Forty Seven Stock
Clinical-stage immuno-oncology company
About Forty Seven Stock
With a passion for pioneering breakthrough solutions, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity.
Lightspeed Venture Partners
WSJ - Feb, 24 2016